Article
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Blood - 15 May 2005
Tseng Ping-Hui, Lin Ho-Pi, Zhu Jiuxiang, Chen Kuen-Feng, Hade Erinn M, Young Donn C, Byrd John C, Grever Michael, Johnson Kara, Druker Brian J, Chen Ching-Shih
Abstract excerpt
Resistance to the Ableson protein tyrosine (Abl) kinase inhibitor imatinib mesylate has become a critical issue for patients in advanced phases of chronic myelogenous leukemia. Imatinib-resistant tumor cells develop, in part, as a result of point mutations within the Abl kinase domain. As protein kinase B (Akt) plays a pivotal role in Abl oncogene-mediated cell survival, we hypothesize that concurrent inhibition...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
